Extensive genome sequencing has revealed genetic alterations of targetable oncogenes in almost 50% of iCCA patients [42] with recurrent alterations in IDH1 [isocitrate dehydrogenase (NADP (+)) 1] and FGFR2 (fibroblast growth factor receptor 2). This evidence concerns the gene IDH1 and infantile convulsions and choreoathetosis.